{"entity":{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","aka":[],"tldr":"Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.","summary":"Andrew Tutt is Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research and a consultant clinical oncologist at The Royal Marsden and Guy's. His specialisms are triple-negative breast cancer, BRCA and DNA repair, PARP inhibitors and platinum chemotherapy. His work on BRCA-deficient breast cancer runs from the first clinical proof-of-concept for a PARP inhibitor, through the TNT trial of carboplatin in BRCA1/2-mutated and triple-negative subgroups reported in Nature Medicine, to OlympiA, the adjuvant olaparib trial in BRCA-mutated breast cancer published in the New England Journal of Medicine. This body of work defined DNA-repair-targeted therapy in breast cancer. His ICR profile and PubMed listing are linked.","asOf":"2026-09-08","links":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-andrew-tutt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tutt%20A%5BAuthor%5D%20olaparib%20breast"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["parp-inhibitor","platinum"],"targets":["brca","parp"],"drugs":["olaparib","carboplatin"],"companies":[],"institutions":["royal-marsden","icr-london","breast-cancer-now"],"pathways":[],"terms":[],"trials":["olympia","tnt"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Breast Cancer Now Toby Robins Research Centre, ICR; Consultant Clinical Oncologist, Royal Marsden and Guy's","institutionId":"royal-marsden","specialisms":["Triple-negative breast cancer","BRCA and DNA repair","PARP inhibitors","Platinum chemotherapy"],"profiles":[{"label":"ICR profile","url":"https://www.icr.ac.uk/research-and-discoveries/our-research/researchers/professor-andrew-tutt"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Tutt%20A%5BAuthor%5D%20olaparib%20breast"}],"papers":[{"title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer (OlympiA)","journal":"NEJM","year":2021,"doi":"10.1056/NEJMoa2105215"},{"title":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","journal":"Nature Medicine","year":2018,"doi":"10.1038/s41591-018-0009-7"}]},"route":"/people/andrew-tutt/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","route":"/institutions/breast-cancer-now/"},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/"},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"trial":[{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/"},{"id":"tnt","kind":"trial","name":"TNT (Triple Negative Trial)","route":"/trials/tnt/"}],"paper":[{"id":"paper-tutt-nat-med","kind":"paper","name":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","route":"/key-papers/paper-tutt-nat-med/"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"},{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/"},{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/"}],"roadmap":[{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"person":[{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/"}]}}